Here are the latest G-BA decisions from the G-BA meeting held on 5 March 2026 on the early benefit assessments of Rezdiffra and Tavneos.
A database of all previous G-BA resolutions is available in my store.
- Rezdiffra (Resmetirome); metabolic dysfunction-associated steatohepatitis (MASH), non-cirrhotic – Additional benefit not proven
- Tavneos (avacopan); re-evaluation of an orphan drug after exceeding the €30 million threshold: granulomatosis with polyangiitis or microscopic polyangiitis, in combination with rituximab or cyclophosphamide – Additional benefit not proven